

# Erectile Dysfunction Market - Global Outlook and Forecast 2021-2026

<https://marketpublishers.com/r/EAD56D14DBBEN.html>

Date: February 2021

Pages: 345

Price: US\$ 3,750.00 (Single User License)

ID: EAD56D14DBBEN

## Abstracts

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Erectile Dysfunction Market Report

The global erectile dysfunction is expected to cross USD 4.7 billion during the period 2021-2026.

The global erectile dysfunction market is expected to observe a negative growth during the forecast period on account of the decline in revenue from the ED therapeutics segment. The presence of several generic companies and the patent expiry of blockbuster ED drugs, including Viagra, Cialis, and Levitra are expected to hamper the growth of ED drugs. However, the overall market is expected to benefit from the steady growth observed in ED devices. The non-invasive nature and no adverse effects profile of shock wave therapy are the primary factors influencing the growth of the ED device market. The increasing focus of vendors in manufacturing new innovative technologies such as vibrators and magnetic therapy for the management of ED is further boosting the ED devices market. The introduction of magnetic therapy for the treatment of ED is likely to drive the demand for ED devices. However, the outbreak of the COVID-19 pandemic and the unavailability of hospitals for penile implantations hindered the ED devices market in 2020. Nevertheless, a high incidence of the disease followed by the wide availability of generic medications and advanced technological advances in ED devices are likely to boost the market during the forecast period.

The following factors are likely to contribute to the growth of the erectile dysfunction market during the forecast period:

Introduction of New ED Treatment Devices

Increase in Strategic Agreements & Collaborations

Advances in ED Drug Formulations

Increase in Incidence of ED and Other Chronic Diseases

The study considers the present scenario of the erectile dysfunction market and its market dynamics for the period 2020-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

### **Global Erectile Dysfunction Market Segmentation**

The global erectile dysfunction market research report includes a detailed segmentation by product, drugs, devices, distribution, geography. Erectile Dysfunction (ED) drugs occupy the major share of the ED drugs market due to their high recommendations by physicians and high efficiency. The advent of topical formulations and innovations in minimal invasive penile suppositories is likely to boost the market during the forecast period. Oral drugs consist of PDE-5 inhibitors, which are considered as the first line treatment option by physicians for the treatment of ED. However, the oral drugs sub-segment is experiencing negative CAGR due to the loss of patent protection.

Oral drugs are found to be more effective and safe drugs and are considered as first-line therapy in treatment of ED. Hence, these drugs account for over 94% share of the market. Innovations in oral PDE-5 inhibitors include novel oral transmucosal drug delivery through oral dispersive tablets or oral dispersible film is expected to boost the market growth during the forecast period. The high prevalence of vascular and chronic diseases such as diabetic, hypertension, and psychological disorders, etc. is likely to influence the segment growth.

Based on device type, penile implants dominate the device market, accounting for over 49% shares, followed by VCD (vacuum constriction devices), and shockwave therapy. Penile implantations are recommended when the patient fails to respond via oral PDE-5 inhibitors or penile injections. Although penile implantations are considered as the last option by physicians, their demand is increasing due to the high efficacy up to 90% satisfactory erection among patients. However, malfunctioning, erosions, infections, lack

of medical expertise about implantation and high cost of implants are expected to hamper the growth of penile implantations.

Retail pharmacies account for the largest share of the global ED drugs market.

Retail pharmacies are considered a major centers to procure medicines. Easy access to medicines and the availability of generic ED drugs via retail pharmacies are increasing the market share of retail pharmacies. Hospital pharmacies constituted over 33% shares in the market. The growing awareness of erectile dysfunction and other sex-related disorders has highly increased revenue of hospitals. Developed countries are the major contributors to hospital pharmacies as patients prefer prescribed medication for ED. However, hospital pharmacies experienced negative growth in 2020 due to the outbreak of the COVID-19 pandemic.

## **Products**

Drugs

Devices

## **Drugs**

Route of Administration

Oral Drugs

Topical Formulation

Penile Injections & Suppositories

Distribution

Hospital Pharmacies

Offline Retail Pharmacies

Online Channels

## Devices

Penile Implants

Vacuum Therapy Devices

Shockwave Therapy

## INSIGHTS BY GEOGRAPHY

The increasing focus on strategic agreements and collaborations is driving the North America ED market. The region accounted for shares of around 37% of the total erectile dysfunction market share. Factors contributing to the growth include better access to erectile dysfunction prescription as well as generic drugs, reimbursement coverage for surgeries in ED, better healthcare infrastructure, increasing in R&D innovations, high demand for ED drugs are likely to drive the market. The US is a major contributor to the North America region, accounting for over 90% of market share. Approximately 18 million men are affected with erectile dysfunction in the US. With the increase in chronic diseases, the incidence of ED is growing. Over 50% and 51.3% people with cardiovascular diseases and diabetes, respectively, are likely to experience erectile dysfunction.

## Geography

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

APAC

China

India

Japan

South Korea

Australia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Saudi Arabia

Turkey

South Africa

## INSIGHTS BY VENDORS

The global ED drugs market is observed to be oligopoly in nature, wherein only few sellers occupy dominant the market share. Pfizer, Eli Lilly and Company, Bayer, Teva Pharmaceuticals, Viatris, Dong-A-Socio Holdings, and Vivus are the key players offering oral ED drugs. Although the blockbuster oral drugs of ED lost their patent protection, the

drugs market is expected to witness a sustainable growth due to the high availability of generic versions. Branded drugs offered by global players are introduced as generic drugs for treating ED. The competitiveness among vendors is significantly high because of the accessibility to a wide range of low-cost generic drugs and OTC topical drug formulations for treating ED. Companies whose patent expired are expected to face strong competition from vendors that are offering generic drugs, topical creams, and non-invasive options.

### **Prominent Vendors**

Eli Lilly and Company

VIVUS

Pfizer

Bayer

Boston Scientific

Coloplast

Teva Pharmaceuticals

Viatis

Dong-A Socio Holdings

### **Other Prominent Vendors**

Aurobindo Pharma

Reddy's Laboratories

Cristalia

Metuchen Pharmaceuticals

Menarini Group

SK Chemicals

Seelos Therapeutics

GlaxoSmithKline

Sanofi

Lupin

Cipla

Sandoz

Endo International

Ferring Pharmaceuticals

ADVANZ PHARMA

Alembic Pharmaceuticals

Guangzhou Pharmaceutical Holdings

iX Biopharma

Dornier MedTech

Zephyr Surgical Implants

Augusta Medical Systems

Launch Medical

Bonro Medical

Owen Mumford

Direx Group

Zimmer Medizin Systeme

MTS Medical UG

Medispec

Incelor Medical

NOVAmedtek

WIKKON

Top Quality Group

Promedon

Timm Medical Technologies

Global Life Technologies

Urology Health Store

Hims

## **KEY QUESTIONS ANSWERED**

1. What is the market size of the erectile dysfunction market during the period 2020-2026?
2. Which new ED devices are introduced for the treatment of erectile dysfunction?
3. What are the threats faced by the existing key players in the ED industry?
4. Which distribution channels is expected to contribute highest revenue to the erectile dysfunction treatment market?
5. Which region to account for the highest incremental revenue during the forecast period?



## Contents

### **1 RESEARCH METHODOLOGY**

### **2 RESEARCH OBJECTIVES**

### **3 RESEARCH PROCESS**

### **4 SCOPE & COVERAGE**

#### 4.1 Market Definition

##### 4.1.1 Inclusions

##### 4.1.2 Exclusion

#### 4.2 Base Year

#### 4.3 Scope of The Study

#### 4.4 Market Segments

##### 4.4.1 Market Segmentation by Product

##### 4.4.2 ED Drugs Market Segmentation by ROA

##### 4.4.3 ED Drugs Market Segmentation by Distribution

##### 4.4.4 ED Devices Market Segmentation by Product

##### 4.4.5 Market Segmentation by Geography

### **5 REPORT ASSUMPTIONS & CAVEATS**

#### 5.1 Key Caveats

#### 5.2 Currency Conversion

#### 5.3 Market Derivation

### **6 MARKET AT A GLANCE**

### **7 INTRODUCTION**

#### 7.1 Overview

##### 7.1.1 Signs & Symptoms Of ED

##### 7.1.2 Classification of ED

##### 7.1.3 Etiology of ED

##### 7.1.4 Epidemiology

##### 7.1.5 Diagnosis & Treatment of ED

##### 7.1.6 ED Treatment

## **8 PIPELINE LANDSCAPE**

- 8.1 Overview
- 8.2 Key Investigational Drugs/Devices
- 8.3 Terminated/Withdrawn Drug/Device Candidates
- 8.4 Key Product Profiles
  - 8.4.1 MED3000
  - 8.4.2 YM178
  - 8.4.3 SST-6006

## **9 MARKETING PRODUCT LANDSCAPE**

- 9.1 Overview
- 9.2 Comparison of ED Pharmaceuticals
  - 9.2.1 Comparison of Pharmacological Drugs For ED
  - 9.2.2 Comparison of ED Devices

## **10 MARKET OPPORTUNITIES & TRENDS**

- 10.1 Emergence Of Innovative Ed Treatment Technologies
- 10.2 Increasing Strategic Agreements & Collaborations
- 10.3 Increase In E-Commerce Delivery Of ED Drugs & Devices
- 10.4 Advancements In ED Drug Formulations

## **11 MARKET GROWTH ENABLERS**

- 11.1 Increasing Incidence Of Erectile Dysfunction And Other Chronic Diseases
- 11.2 Advancements In Erectile Dysfunction Treatment Devices
- 11.3 Topical Formulation As A New Treatment For Impotence

## **12 MARKET RESTRAINTS**

- 12.1 Low Patient Compliance Toward ED Treatment
- 12.2 Key Patent Expiries & Availability Of Low-Cost Generics
- 12.3 Complications Associated With Erectile Drugs & Devices
- 12.4 Availability Of Alternative Treatments For ED
- 12.5 Threat From Counterfeit Drugs In Treating Erectile Dysfunction

## **13 MARKET LANDSCAPE**

- 13.1 Market Overview
- 13.2 Market Size & Forecast
- 13.3 Five Forces Analysis
  - 13.3.1 Threat of New Entrants
  - 13.3.2 Bargaining Power of Suppliers
  - 13.3.3 Bargaining Power of Buyers
  - 13.3.4 Threat of Substitutes
  - 13.3.5 Competitive Rivalry

## **14 PRODUCT**

- 14.1 Market Snapshot & Growth Engine
- 14.2 Market Overview

## **15 DRUGS**

- 15.1 Market Overview
  - 15.1.1 COVID-19 Impact on Erectile Dysfunction Drugs Market
- 15.2 Market Size & Forecast
- 15.3 Drugs: ROA Segmentation
  - 15.3.1 Oral Drugs: Market Size & Forecast
  - 15.3.2 Penile Injections and Intraurethral Suppositories: Market Size & Forecast
  - 15.3.3 Topical Formulations: Market Size & Forecast
- 15.4 Drugs: Distribution Channel Segmentation
  - 15.4.1 Market Snapshot & Growth Engine
  - 15.4.2 Retail Pharmacies: Market Size & Forecast
  - 15.4.3 Hospital Pharmacies: Market Size & Forecast
  - 15.4.4 Online Portals: Market Size & Forecast
- 15.5 Drugs: Geography Segmentation
  - 15.5.1 Market Snapshot & Growth Engine

## **16 DEVICES**

- 16.1 Market Overview
  - 16.1.1 COVID-19 Impact on Erectile Dysfunction Devices Market
- 16.2 Market Size & Forecast
- 16.3 Devices: Device Type Segmentation

- 16.3.1 Market Snapshot & Growth Engine
- 16.3.2 Penile Implants: Market Size & Forecast
- 16.3.3 Vacuum Constriction Devices: Market Size & Forecast
- 16.3.4 Shock Wave Therapy Devices: Market Size & Forecast
- 16.3.5 Others: Market Size & Forecast
- 16.4 Devices: Geography Segmentation
  - 16.4.1 Market Snapshot & Growth Engine

## **17 GEOGRAPHY**

- 17.1 Market Snapshot & Growth Engine
- 17.2 Geographic Overview

## **18 NORTH AMERICA**

- 18.1 Market Overview
- 18.2 Market Size & Forecast
- 18.3 Key Countries
  - 18.3.1 US: Market Size & Forecast
  - 18.3.2 Canada: Market Size & Forecast

## **19 EUROPE**

- 19.1 Market Overview
- 19.2 Market Size & Forecast
- 19.3 Key Countries
  - 19.3.1 UK: Market Size & Forecast
  - 19.3.2 Germany: Market Size & Forecast
  - 19.3.3 France: Market Size & Forecast
  - 19.3.4 Italy: Market Size & Forecast
  - 19.3.5 Spain: Market Size & Forecast

## **20 APAC**

- 20.1 Market Overview
- 20.2 Market Size & Forecast
- 20.3 Key Countries
  - 20.3.1 Japan: Market Size & Forecast
  - 20.3.2 China: Market Size & Forecast

- 20.3.3 India: Market Size & Forecast
- 20.3.4 Australia: Market Size & Forecast
- 20.3.5 South Korea: Market Size & Forecast

## **21 LATIN AMERICA**

- 21.1 Market Overview
- 21.2 Market Size & Forecast
- 21.3 Key Countries
  - 21.3.1 Brazil: Market Size & Forecast
  - 21.3.2 Mexico: Market Size & Forecast
  - 21.3.3 Argentina: Market Size & Forecast

## **22 MIDDLE EAST & AFRICA**

- 22.1 Market Overview
- 22.2 Market Size & Forecast
- 22.3 Key Countries
  - 22.3.1 Saudi Arabia: Market Size & Forecast
  - 22.3.2 UAE: Market Size & Forecast
  - 22.3.3 South Africa: Market Size & Forecast

## **23 COMPETITIVE LANDSCAPE**

- 23.1 Competitive Overview
  - 23.1.1 Overview of ED Drugs
  - 23.1.2 Overview of ED Devices
- 23.2 Market Share Analysis
  - 23.2.1 Bayer
  - 23.2.2 Boston Scientific
  - 23.2.3 Coloplast
  - 23.2.4 Dong-A-Socio Holdings
  - 23.2.5 Eli Lilly and Company
  - 23.2.6 Pfizer
  - 23.2.7 Teva Pharmaceuticals
  - 23.2.8 Viatris
  - 23.2.9 Vivus

## **24 KEY COMPANY PROFILES**

## 24.1 Eli Lilly and Company

### 24.1.1 Business Overview

### 24.1.2 Product Offerings

### 24.1.3 Key Strategies

### 24.1.4 Key Strengths

### 24.1.5 Key Opportunities

## 24.2 Vivus

### 24.2.1 Business Overview

### 24.2.2 Product Offerings

### 24.2.3 Key Strategies

### 24.2.4 Key Strengths

### 24.2.5 Key Opportunities

## 24.3 Pfizer

### 24.3.1 Business Overview

### 24.3.2 Product Offerings

### 24.3.3 Key Strategies

### 24.3.4 Key Strengths

### 24.3.5 Key Opportunities

## 24.4 Bayer

### 24.4.1 Business Overview

### 24.4.2 Product Offerings

### 24.4.3 Key Strategies

### 24.4.4 Key Strengths

### 24.4.5 Key Opportunities

## 24.5 Boston Scientific

### 24.5.1 Business Overview

### 24.5.2 Product Offerings

### 24.5.3 Key Strategies

### 24.5.4 Key Strengths

### 24.5.5 Key Opportunity

## 24.6 Coloplast

### 24.6.1 Business Overview

### 24.6.2 Product Offerings

### 24.6.3 Key Strategies

### 24.6.4 Key Strengths

### 24.6.5 Key Opportunities

## 24.7 Teva Pharmaceuticals

### 24.7.1 Business Overview

24.7.2 Product Offerings

24.7.3 Key Strategies

24.7.4 Key Strengths

24.7.5 Key Opportunities

24.8 Viatris

24.8.1 Business Overview

24.8.2 Product Offerings

24.8.3 Key Strategies

24.8.4 Key Strengths

24.8.5 Key Opportunity

24.9 Dong–A Socio Holdings

24.9.1 Business Overview

24.9.2 Product Offerings

24.9.3 Key Strategies

24.9.4 Key Strength

24.9.5 Key Opportunity

## **25 OTHER PROMINENT VENDORS**

25.1 Aurobindo Pharma

25.1.1 Business Overview

25.1.2 Product Offerings

25.1.3 Key Strategies

25.1.4 Key Strengths

25.1.5 Key Opportunities

25.2 Dr. Reddy's Laboratories

25.2.1 Business Overview

25.2.2 Product Offerings

25.2.3 Key Strategies

25.2.4 Key Strengths

25.2.5 Key Opportunities

25.3 Cristalia

25.3.1 Business Overview

25.3.2 Product Offerings

25.3.3 Key Strategies

25.3.4 Key Strengths

25.3.5 Key Opportunity

25.4 Metuchen Pharmaceuticals

25.4.1 Business Overview

- 25.4.2 Product Offerings
- 25.4.3 Key Strategies
- 25.4.4 Key Strength
- 25.4.5 Key Opportunity
- 25.5 Menarini Group
  - 25.5.1 Business Overview
  - 25.5.2 Product Offerings
  - 25.5.3 Key Strategies
  - 25.5.4 Key Strengths
  - 25.5.5 Key Opportunity
- 25.6 SK chemicals
  - 25.6.1 Business Overview
  - 25.6.2 Product Offerings
  - 25.6.3 Key Strategies
  - 25.6.4 Key Strengths
  - 25.6.5 Key Opportunities
- 25.7 Seelos Therapeutics
  - 25.7.1 Business Overview
  - 25.7.2 Product Offerings
  - 25.7.3 Key Strategies
  - 25.7.4 Key Strengths
  - 25.7.5 Key Opportunities
- 25.8 GlaxoSmithKline
  - 25.8.1 Business Overview
  - 25.8.2 Product Offerings
  - 25.8.3 Key Strategies
  - 25.8.4 Key Strengths
  - 25.8.5 Key Opportunity
- 25.9 Sanofi
  - 25.9.1 Business Overview
  - 25.9.2 Product Offerings
  - 25.9.3 Key Strategy
  - 25.9.4 Key Strengths
  - 25.9.5 Key Opportunities
- 25.10 Lupin
  - 25.10.1 Business Overview
  - 25.10.2 Product Offerings
  - 25.10.3 Key Strategies
  - 25.10.4 Key Strengths



- 25.10.5 Key Opportunity
- 25.11 Cipla
  - 25.11.1 Business Overview
  - 25.11.2 Product Offerings
  - 25.11.3 Key Strategies
  - 25.11.4 Key Strengths
  - 25.11.5 Key Opportunities
- 25.12 Sandoz
  - 25.12.1 Business Overview
  - 25.12.2 Product Offering
  - 25.12.3 Key Strategies
  - 25.12.4 Key Strengths
  - 25.12.5 Key Opportunity
- 25.13 Endo International
  - 25.13.1 Business Overview
  - 25.13.2 Product Offerings
  - 25.13.3 Key Strategies
  - 25.13.4 Key Strengths
  - 25.13.5 Key Opportunities
- 25.14 Ferring Pharmaceuticals
  - 25.14.1 Business Overview
  - 25.14.2 Product Offerings
  - 25.14.3 Key Strategies
  - 25.14.4 Key Strengths
  - 25.14.5 Key Opportunity
- 25.15 ADVANZ PHARMA
  - 25.15.1 Business Overview
  - 25.15.2 Product Offerings
  - 25.15.3 Key Strategy
  - 25.15.4 Key Strengths
  - 25.15.5 Key Opportunities
- 25.16 Alembic Pharmaceuticals
  - 25.16.1 Business Overview
  - 25.16.2 Product Offerings
  - 25.16.3 Key Strategies
  - 25.16.4 Key Strength
  - 25.16.5 Key Opportunities
- 25.17 Guangzhou Pharmaceutical Holdings
  - 25.17.1 Business Overview

- 25.17.2 Product Offerings
- 25.17.3 Key Strategy
- 25.17.4 Key Strengths
- 25.17.5 Key Opportunity
- 25.18 iX Biopharma
  - 25.18.1 Business Overview
  - 25.18.2 Product Offerings
  - 25.18.3 Key Strategy
  - 25.18.4 Key Strengths
  - 25.18.5 Key Opportunities
- 25.19 Dornier MedTech
  - 25.19.1 Business Overview
  - 25.19.2 Product Offerings
  - 25.19.3 Key Strategies
  - 25.19.4 Key Strengths
  - 25.19.5 Key Opportunity
- 25.20 Zephyr Surgical Implants
  - 25.20.1 Business Overview
  - 25.20.2 Product Offerings
  - 25.20.3 Key Strategies
  - 25.20.4 Key Strengths
  - 25.20.5 Key Opportunity
- 25.21 Augusta Medical Systems
  - 25.21.1 Business Overview
  - 25.21.2 Product Offerings
  - 25.21.3 Key Strategy
  - 25.21.4 Key Strength
  - 25.21.5 Key Opportunity
- 25.22 Launch Medical
  - 25.22.1 Business Overview
  - 25.22.2 Product Offerings
  - 25.22.3 Key Strategy
  - 25.22.4 Key Strength
  - 25.22.5 Key Opportunity
- 25.23 Bonro Medical
  - 25.23.1 Business Overview
  - 25.23.2 Product Offerings
  - 25.23.3 Key Strategy
  - 25.23.4 Key Strength

- 25.23.5 Key Opportunity
- 25.24 Owen Mumford
  - 25.24.1 Business Overview
  - 25.24.2 Product Offerings
  - 25.24.3 Key Strategies
  - 25.24.4 Key Strengths
  - 25.24.5 Key Opportunity
- 25.25 Direx Group
  - 25.25.1 Business Overview
  - 25.25.2 Product Offerings
  - 25.25.3 Key Strategy
  - 25.25.4 Key Strength
  - 25.25.5 Key Opportunity
- 25.26 Zimmer Medizin Systeme
  - 25.26.1 Business Overview
  - 25.26.2 Product Offerings
  - 25.26.3 Key Strategies
  - 25.26.4 Key Strengths
  - 25.26.5 Key Opportunity
- 25.27 MTS Medical UG
  - 25.27.1 Business Overview
  - 25.27.2 Product Offerings
  - 25.27.3 Key Strategy
  - 25.27.4 Key Strengths
  - 25.27.5 Key Opportunity
- 25.28 Medispec
  - 25.28.1 Business Overview
  - 25.28.2 Product Offerings
  - 25.28.3 Key Strategies
  - 25.28.4 Key Strengths
  - 25.28.5 Key Opportunity
- 25.29 Inceler Medical
  - 25.29.1 Business Overview
  - 25.29.2 Product Offerings
  - 25.29.3 Key Strategies
  - 25.29.4 Key Strength
  - 25.29.5 Key Opportunity
- 25.30 NOVAmедtek
  - 25.30.1 Business Overview

- 25.30.2 Product Offerings
- 25.30.3 Key Strategy
- 25.30.4 Key Strength
- 25.30.5 Key Opportunity
- 25.31 WIKKON
  - 25.31.1 Business Overview
  - 25.31.2 Product Offering
  - 25.31.3 Key Strategy
  - 25.31.4 Key Strengths
  - 25.31.5 Key Opportunity
- 25.32 Top Quality Group
  - 25.32.1 Business Overview
  - 25.32.2 Product Offerings
  - 25.32.3 Key Strategy
  - 25.32.4 Key Strengths
  - 25.32.5 Key Opportunity
- 25.33 Promedon
  - 25.33.1 Business Overview
  - 25.33.2 Product Offerings
  - 25.33.3 Key Strategy
  - 25.33.4 Key Strengths
  - 25.33.5 Key Opportunities
- 25.34 Timm medical technologies
  - 25.34.1 Business Overview
  - 25.34.2 Product Offerings
  - 25.34.3 Key Strategy
  - 25.34.4 Key Strength
  - 25.34.5 Key Opportunity
- 25.35 Global Life Technologies
  - 25.35.1 Business Overview
  - 25.35.2 Product Offerings
  - 25.35.3 Key Strategy
  - 25.35.4 Key Strength
  - 25.35.5 Key Opportunity
- 25.36 Urology Health Store
  - 25.36.1 Business Overview
  - 25.36.2 Product Offering
  - 25.36.3 Key Strategy
  - 25.36.4 Key Strength

25.36.5 Key Opportunity

25.37 Hims

25.37.1 Business Overview

25.37.2 Product Offerings

25.37.3 Key Strategy

25.37.4 Key Strength

25.37.5 Key Opportunity

## **26 REPORT SUMMARY**

26.1 Key Takeaways

26.2 Strategic Recommendations

## **27 QUANTITATIVE SUMMARY**

27.1 Product

27.2 Geography

27.2.1 North America: Product Segmentation

27.2.2 Europe: Product Segmentation

27.2.3 APAC: Product Segmentation

27.2.4 Latin America: Product Segmentation

27.2.5 Middle East & Africa: Product Segmentation

27.3 ED Drugs

27.3.1 ED Drugs: ROA Segmentation

27.3.2 ED Drugs: Distribution Channel Segmentation

27.3.3 ED Drugs: Geography Segmentation

27.4 ED Devices

27.4.1 ED Devices: Product Segmentation

27.4.2 ED Devices: Geography Segmentation

## **28 APPENDIX**

28.1 Abbreviations

## List Of Exhibits

### LIST OF EXHIBITS

- Exhibit 1 Segmentation of Global Erectile Dysfunction Treatment Market
- Exhibit 2 Market Size Calculation Approach 2020
- Exhibit 3 Schematic Representation of Penile Erection
- Exhibit 4 Pathophysiology of Erectile Dysfunction
- Exhibit 5 Signs and Symptoms of Erectile Dysfunction
- Exhibit 6 ED Classification according to International Society of Impotence Research
- Exhibit 7 Etiology of Erectile Dysfunction
- Exhibit 8 Global Increasing Prevalence of ED 1995& 2025 (in million)
- Exhibit 9 Clinical Evaluation in Patients Suffering from ED
- Exhibit 10 Treatment Algorithm for ED
- Exhibit 11 Impact of Emergence of Innovative ED Treatment Technologies
- Exhibit 12 Impact of Increasing Strategic Agreements & Collaborations
- Exhibit 13 Impact of Increasing in e-Commerce Delivery of ED Drugs & Devices
- Exhibit 14 Global E-Pharmacy Revenue 2019 & 2027 (in billion)
- Exhibit 15 Factors Driving the Utilization of E-pharmacy Platform among the Patient Population
- Exhibit 16 Impact of Advancements in ED Drug Formulations
- Exhibit 17 Impact of Increasing Incidence of Erectile Dysfunction and Other Chronic Diseases
- Exhibit 18 Prevalence Rate of ED in Different Geographic Regions (%)
- Exhibit 19 Increasing Global Erectile Dysfunction Prevalence (1995 & 2025) (million)
- Exhibit 20 Prevalence of Erectile Dysfunction with Age (%)
- Exhibit 21 Prevalence of Benign Prostatic Hyperplasia (BPH) in Different Geographies (%)
- Exhibit 22 Increasing Prevalence of Diabetes Mellitus (2019-2045) (million)
- Exhibit 23 Impact of Advancements in Erectile Dysfunction Treatment Devices
- Exhibit 24 Various Non-Pharmacological Options for ED Treatment
- Exhibit 25 Impact of Topical Formulations as a New Treatment for Impotence
- Exhibit 26 Impact of Low Patient Compliance toward ED Treatment
- Exhibit 27 Prevalence of ED in US and Spain (70-75 Years Old Men)
- Exhibit 28 Percentage of Health-seeking Rate for ED (20-75 Years Old) in US & Germany
- Exhibit 29 Factors Affecting Medical Help-seeking Behavior in ED Patients
- Exhibit 30 Willingness to Discuss ED According to its Severity (%)
- Exhibit 31 Impact of Key Patent Expiries & Availability of Low-cost Generics

- Exhibit 32 Pfizer's Viagra Revenue 2015-2019 (\$ million)
- Exhibit 33 Eli Lilly and Company's Cialis (Tadalafil) Revenue in US (\$ million)
- Exhibit 34 Impact of Complications Associated with Erectile Drugs & Devices
- Exhibit 35 Complications Associated with Alprostadil Injection
- Exhibit 36 Side effects and Serious Adverse Events Associated with PDE-5 Inhibitors
- Exhibit 37 Adverse Reactions Associated with Erectile Devices
- Exhibit 38 Impact of Availability of Alternative Treatments for ED
- Exhibit 39 Alternative Treatment Options for Erectile Dysfunction
- Exhibit 40 Impact of Threat from Counterfeit Drugs in Treating Erectile Dysfunction
- Exhibit 41 Factors Contributing to Large Counterfeit Version Market in Erectile Dysfunction
- Exhibit 42 Factors Responsible for the Purchase of Counterfeit Version of Medicines in Erectile Dysfunction
- Exhibit 43 Global Erectile Dysfunction Treatment Market 2020–2026 (\$ million)
- Exhibit 44 Global Erectile Dysfunction Treatment Market by Geography
- Exhibit 45 Global Erectile Dysfunction Treatment Market by Product
- Exhibit 46 Global Erectile Dysfunction Drugs Market by ROA
- Exhibit 47 Erectile Dysfunction Devices Market by Product
- Exhibit 48 Five Forces Analysis 2020
- Exhibit 49 Incremental Growth by Product 2020 & 2026
- Exhibit 50 Global Erectile Dysfunction Treatment Market by Product
- Exhibit 51 Global Erectile Dysfunction Treatment Market by Product: Incremental Growth
- Exhibit 52 Global Erectile Dysfunction Treatment Market by Product: Absolute Growth
- Exhibit 53 Global ED Drugs Market 2020–2026 (\$ million)
- Exhibit 54 Incremental Growth by ROA 2020 & 2026
- Exhibit 55 Global Erectile Dysfunction Treatment Market by ROA
- Exhibit 56 Common PDE-5 Inhibitors Used in the Treatment of Erectile Dysfunction
- Exhibit 57 Global Erectile Dysfunction Drugs Market by Oral Drugs 2020–2026 (\$ million)
- Exhibit 58 Global ED Drugs Market by Penile Injections and Intraurethral Suppositories 2020–2026 (\$ million)
- Exhibit 59 Companies Offering Penile Injections and Intraurethral Suppositories for Treating ED
- Exhibit 60 Advantages with Topical Formulations over PDE-5 Inhibitors for the Treatment of ED
- Exhibit 61 Global ED Drugs Market by Topical Formulations
- Exhibit 62 Incremental Growth by Distribution Channel 2020 & 2026
- Exhibit 63 Global Erectile Dysfunction Drugs Market by Distribution



- Exhibit 64 Global ED Drugs Market by Retail Pharmacies 2020–2026 (\$ million)
- Exhibit 65 Global ED Drugs Market by Hospital Pharmacies 2020–2026 (\$ million)
- Exhibit 66 Global ED Drugs Market by Online Pharmacies 2020–2026 (\$ million)
- Exhibit 67 Incremental Growth by Geography 2020 & 2026
- Exhibit 68 Global ED Devices Market 2020–2026 (\$ million)
- Exhibit 69 Incremental Growth by Device Type 2020 & 2026
- Exhibit 70 Global Erectile Dysfunction Treatment Market by Device Type
- Exhibit 71 Advantages with Penile Implantation in the Treatment of Impotence
- Exhibit 72 Global ED Devices Market by Penile Implants 2020–2026 (\$ million)
- Exhibit 73 Advantages with Vacuum Construction Devices in Treatment of Erectile Dysfunction
- Exhibit 74 Global ED Devices Market by Vacuum Constriction Devices 2020–2026 (\$ million)
- Exhibit 75 Benefits with Low-intensity Shock Wave Therapy for ED
- Exhibit 76 Global ED Devices Market by Shock Wave Therapy 2020–2026 (\$ million)
- Exhibit 77 Global ED Devices Market by Others Segment 2020–2026 (\$ million)
- Exhibit 78 Incremental Growth by Geography 2020 & 2026
- Exhibit 79 Incremental Growth by Geography 2020 & 2026
- Exhibit 80 Global Erectile Dysfunction Treatment Market by Geography
- Exhibit 81 Global Erectile Dysfunction Treatment Market by Geography 2020: Key Countries (\$ million)
- Exhibit 82 Global Erectile Dysfunction Treatment Market by Geography: Incremental Growth
- Exhibit 83 Global Erectile Dysfunction Treatment Market by Geography: Absolute Growth
- Exhibit 84 Erectile Dysfunction Treatment Market in North America 2020–2026 (\$ million)
- Exhibit 85 Incremental Growth in North America 2020 & 2026
- Exhibit 86 Prevalence of ED Treatment in Accordance with Age in US
- Exhibit 87 Prevalence of Co-morbidities with and without ED in US
- Exhibit 88 Erectile Dysfunction Treatment Market in US 2020–2026 (\$ million)
- Exhibit 89 Impact of Patent Expiration on Viagra and Cialis Revenue Rates 2017–2019 (in million)
- Exhibit 90 Penile Implantation According to Region
- Exhibit 91 Percent Probability of ED with Co-morbid Conditions in Men aged 40-49
- Exhibit 92 Erectile Dysfunction Treatment Market in Canada 2020–2026 (\$ million)
- Exhibit 93 Erectile Dysfunction Treatment Market in Europe 2020–2026 (\$ million)
- Exhibit 94 Incremental Growth in Europe 2020 & 2026
- Exhibit 95 Erectile Dysfunction Treatment Market in UK 2020–2026 (\$ million)



- Exhibit 96 Percentage of Prevalence of Erectile Dysfunction in Germany with Age (30–80 years)
- Exhibit 97 Source of Potency of ED Drugs in Germany
- Exhibit 98 Erectile Dysfunction Treatment Market in Germany 2020–2026 (\$ million)
- Exhibit 99 Erectile Dysfunction Treatment Market in France 2020–2026 (\$ million)
- Exhibit 100 Erectile Dysfunction Treatment Market in Italy 2020–2026 (\$ million)
- Exhibit 101 Prevalence Percentage of Erectile Dysfunction with Respect to Age in Spain
- Exhibit 102 Erectile Dysfunction Treatment Market in Spain 2020–2026 (\$ million)
- Exhibit 103 Erectile Dysfunction Treatment Market in APAC 2020?2026 (\$ million)
- Exhibit 104 Incremental Growth in APAC 2020 & 2026
- Exhibit 105 Erectile Dysfunction Treatment Market in Japan 2020–2026 (\$ million)
- Exhibit 106 Erectile Dysfunction Treatment Market in China 2020–2026 (\$ million)
- Exhibit 107 Erectile Dysfunction Treatment Market in India 2020–2026 (\$ million)
- Exhibit 108 Erectile Dysfunction Treatment Market in Australia 2020?2026 (\$ million)
- Exhibit 109 Erectile Dysfunction Treatment Market in South Korea 2020?2026 (\$ million)
- Exhibit 110 Erectile Dysfunction Treatment Market in Latin America 2020–2026 (\$ million)
- Exhibit 111 Incremental Growth in Latin America 2020 & 2026
- Exhibit 112 Erectile Dysfunction Treatment Market in Brazil 2020–2026 (\$ million)
- Exhibit 113 Erectile Dysfunction Treatment Market in Mexico 2020?2026 (\$ million)
- Exhibit 114 Erectile Dysfunction Treatment Market in Argentina 2020–2026 (\$ million)
- Exhibit 115 Erectile Dysfunction Treatment Market in MEA 2020–2026 (\$ million)
- Exhibit 116 Incremental Growth in Middle East & Africa 2020 & 2026
- Exhibit 117 Erectile Dysfunction Treatment Market in Saudi Arabia 2020–2026 (\$ million)
- Exhibit 118 Erectile Dysfunction Treatment Market in UAE 2020–2026 (\$ million)
- Exhibit 119 Erectile Dysfunction Treatment Market in South Africa 2020–2026 (\$ million)
- Exhibit 120 Key Vendors offering ED Devices
- Exhibit 121 Eli Lilly and Company: Revenue Generated by Human Pharmaceutical Segment 2018 & 2019 (\$ million)
- Exhibit 122 Eli Lilly and Company Revenue Share by Region 2018 & 2019 (\$ million)
- Exhibit 123 Eli Lilly and Company R&D Investments 2017?2019 (\$ million)
- Exhibit 124 Eli Lilly and Company: Revenue for Cialis (tadalafil) in US 2017?2019 (\$ million)
- Exhibit 125 Vivus: Revenue Data 2017?2019 (\$ million)
- Exhibit 126 Vivus: R&D Investments from 2017?2019 (\$ million)
- Exhibit 127 Vivus: Revenue by Geographic Region 2019 (%)
- Exhibit 128 Vivus: Revenue by Stendra/Spedra 2017?2019 (\$ million)

- Exhibit 129 Pfizer: R&D Investments 2017?2019 (\$ million)
- Exhibit 130 Pfizer: Revenue by Segment 2018 & 2019 (\$ million)
- Exhibit 131 Pfizer: Revenue by Geographical Regions 2019 (%)
- Exhibit 132 Pfizer: Revenue by Viagra (Sildenafil citrate) 2017?2019 (\$ million)
- Exhibit 133 Bayer: Revenue 2017?2019 (\$ million)
- Exhibit 134 Bayer: R&D Investments 2017?2019 (\$ million)
- Exhibit 135 Bayer: Revenue by Segment 2018 & 2019 (\$ million)
- Exhibit 136 Bayer: Revenue by Geographic Regions 2019 (%)
- Exhibit 137 Boston Scientific: Revenue in 2017?2019 (\$ million)
- Exhibit 138 Boston Scientific: R&D Expenses 2017?2019 (\$ million)
- Exhibit 139 Boston Scientific: Revenue by Segment 2018 & 2019 (\$ million)
- Exhibit 140 Boston Scientific: Revenue by Region in 2019 (%)
- Exhibit 141 Coloplast: Revenue 2017?2019 (\$ million)
- Exhibit 142 Coloplast: R&D Investments 2017?2019 (\$ million)
- Exhibit 143 Coloplast: Revenue by Segments 2018 & 2019 (\$ million)
- Exhibit 144 Coloplast: Revenue by Region 2019 (%)
- Exhibit 145 Teva Pharmaceuticals: Revenue 2017?2019 (\$ million)
- Exhibit 146 Teva Pharmaceuticals: R&D Investments 2017?2019 (\$ million)
- Exhibit 147 Teva Pharmaceuticals: Revenue by Regions in 2018 & 2019 (in million)
- Exhibit 148 Viatris: Total Revenue 2017?2019 (\$ million)
- Exhibit 149 Viatris: Revenue by Region 2019 (%)
- Exhibit 150 Dong- A-Socio Holdings: Revenue 2017?2019 (\$ million)
- Exhibit 151 Dong-A-Socio Holding: R&D Investments 2017?2019 (\$ million)

## List Of Tables

### LIST OF TABLES

Table 1 Key Caveats

Table 2 Currency Conversion 2013?2020

Table 3 Popular Definitions of Erectile Dysfunction

Table 4 Etiology of ED According to its Sub-type

Table 5 Investigational Drugs/Devices for the Treatment of Erectile Dysfunction

Table 6 Withdrawn/ Terminated Drug Candidates or Devices

Table 7 Comparison of Pharmacological Drugs for Treating ED

Table 8 Different Companies and their Products with Advanced & Innovative Technologies

Table 9 Key Strategic Agreements & Collaborations in Erectile Dysfunction Treatment Market

Table 10 Companies and their Products Offering Novel Erectile Dysfunction Drug Formulations

Table 11 Adverse Events & Limitations of Phosphodiesterase-5 (PDE-5) Inhibitors

Table 12 Efficacy and Safety Profile of Topical Alprostadil Cream for the Treatment of ED

Table 13 Different Companies and their Product Expiry Date

Table 14 Comparing the Activity of Popular PDE-5 Inhibitors

Table 15 Significant Vendors Offering PDE-5 Inhibitors for ED Treatment

Table 16 Significant Players Offering Penile Implants

Table 17 Significant Vendors Offering Vacuum Constriction Devices

Table 18 List of Companies Offering Low-intensity Shock Wave Therapy Products for ED

Table 19 Erectile Dysfunction Treatment Market in US by Product 2020?2026 (\$ million)

Table 20 Erectile Dysfunction Treatment Market in Canada by Product 2020?2026 (\$ million)

Table 21 Ratio Rates of Minimal, Moderate, and Complete ED with Medical Condition

Table 22 Erectile Dysfunction Treatment Market in UK by Product 2020?2026 (\$ million)

Table 23 Erectile Dysfunction Treatment Market in Germany by Product 2020?2026 (\$ million)

Table 24 Erectile Dysfunction Treatment Market in France by Product 2020?2026 (\$ million)

Table 25 Erectile Dysfunction Treatment Market in Italy by Product 2020?2026 (\$ million)

Table 26 Erectile Dysfunction Treatment Market in Spain by Product 2020?2026 (\$

million)

Table 27 Erectile Dysfunction Treatment Market in Japan by Product 2020?2026 (\$ million)

Table 28 Erectile Dysfunction Treatment Market in China by Product 2020?2026 (\$ million)

Table 29 Erectile Dysfunction Treatment Market in India by Product 2020?2026 (\$ million)

Table 30 Erectile Dysfunction Treatment Market in Australia by Product 2020?2026 (\$ million)

Table 31 Erectile Dysfunction Treatment Market in South Korea by Product 2020?2026 (\$ million)

Table 32 Erectile Dysfunction Treatment Market in Brazil by Product 2020?2026 (\$ million)

Table 33 Erectile Dysfunction Treatment Market in Mexico by Product 2020?2026 (\$ million)

Table 34 Erectile Dysfunction Treatment Market in Argentina by Product 2020?2026 (\$ million)

Table 35 Erectile Dysfunction Treatment Market in Saudi Arabia by Product 2020?2026 (\$ million)

Table 36 Erectile Dysfunction Treatment Market in UAE by Product 2020?2026 (\$ million)

Table 37 Erectile Dysfunction Treatment Market in South Africa by Product 2020?2026 (\$ million)

Table 38 Key Vendors in ED Drugs Market

Table 39 Other Prominent Vendors Offering ED Drugs

Table 40 Vendors Offering Various ED Devices

Table 41 Eli Lilly and Company: Major Product Offerings

Table 42 Vivus: Major Product Offerings

Table 43 Pfizer: Major Product Offerings

Table 44 Bayer: Major Product Offerings

Table 45 Boston Scientific: Major Product Offerings

Table 46 Coloplast: Major Product Offerings

Table 47 Teva Pharmaceuticals: Major Product Offerings

Table 48 Viatris: Major Product Offerings

Table 49 Dong-A Socio Holdings: Major Product Offerings

Table 50 Aurobindo Pharma: Major Product Offerings

Table 51 Dr. Reddy's Laboratories: Major Product Offerings

Table 52 Cristalia: Major Product Offerings

Table 53 Metuchen Pharmaceuticals: Major Product Offerings

Table 54 Menarini Group: Major Product Offerings
Table 55 SK Chemicals: Major Product Offerings
Table 56 Seelos Therapeutics: Major Product Offerings
Table 57 GlaxoSmithKline: Major Product Offerings
Table 58 Sanofi: Major Product Offerings
Table 59 Lupin: Major Product Offerings
Table 60 Cipla: Major Product Offerings
Table 61 Sandoz: Major Product Offerings
Table 62 Endo International: Major Product Offerings
Table 63 Ferring Pharmaceuticals: Major Product Offerings
Table 64 ADVANZ PHARMA: Major Product Offerings
Table 65 Alembic Pharmaceuticals: Major Product Offerings
Table 66 Guangzhou Pharmaceutical Holdings: Major Product Offerings
Table 67 iX Biopharma: Major Product Offerings
Table 68 Dornier MedTech: Major Product Offerings
Table 69 Zephyr Surgical Implants: Major Product Offerings
Table 70 Augusta Medical Systems: Major Product Offerings
Table 71 Launch Medical: Major Product Offerings
Table 72 Bonro Medical: Major Product Offerings
Table 73 Owen Mumford: Major Product Offerings
Table 74 Direx Group: Major Product Offerings
Table 75 Zimmer Medizin Systeme: Major Product Offerings
Table 76 MTS Medical UG: Major Product Offerings
Table 77 Medispec: Major Product Offerings
Table 78 Inceler Medical: Major Product Offerings
Table 79 NOVAMEDTEK: Major Product Offerings
Table 80 WIKKON: Major Product Offerings
Table 81 Top Quality Group: Major Product Offerings
Table 82 Promedon: Major Product Offerings
Table 83 Timm medical technologies: Major Product Offerings
Table 84 Global Life Technologies: Major Product Offerings
Table 85 Urology Health Store: Major Product Offerings
Table 86 Hims: Major Product Offerings
Table 87 Global Erectile Dysfunction Market by Product 2020?2026 (\$ million)
Table 88 Global Erectile Dysfunction Market by Product 2020?2026 (%)
Table 89 Global Erectile Dysfunction Treatment Market by Geography 2020?2026 (\$ million)
Table 90 Global Erectile Dysfunction Treatment Market by Geography 2020?2026 (%)
Table 91 North America Erectile Dysfunction Treatment Market by Product 2020?2026

(\$ million)

Table 92 North America Erectile Dysfunction Treatment Market by Product 2020?2026 (%)

Table 93 Europe Erectile Dysfunction Treatment Market by Product 2020?2026 (\$ million)

Table 94 Europe Erectile Dysfunction Treatment Market by Product 2020?2026 (%)

Table 95 APAC Erectile Dysfunction Treatment Market by Product 2020?2026 (\$ million)

Table 96 APAC Erectile Dysfunction Treatment Market by Product 2020?2026 (%)

Table 97 Latin America Erectile Dysfunction Treatment Market by Product 2020?2026 (\$ million)

Table 98 Latin America Erectile Dysfunction Treatment Market by Product 2020?2026 (%)

Table 99 Middle East & Africa Erectile Dysfunction Treatment Market by Product 2020?2026 (\$ million)

Table 100 Middle East & Africa Erectile Dysfunction Treatment Market by 2020?2026 (%)

Table 101 Global Erectile Dysfunction Drugs Market by ROA 2020?2026 (\$ million)

Table 102 Global Erectile Dysfunction Drugs Market by ROA 2020?2026 (%)

Table 103 Global Erectile Dysfunction Drugs Market by Distribution Channel 2020?2026 (\$ million)

Table 104 Global Erectile Dysfunction Drugs Market by Distribution Channel 2020?2026 (%)

Table 105 Global Erectile Dysfunction Drugs Market by Geography 2020?2026 (\$ million)

Table 106 Global Erectile Dysfunction Drugs Market by Geography 2020?2026 (%)

Table 107 Global Erectile Dysfunction Devices Market by Product 2020?2026 (\$ million)

Table 108 Global Erectile Dysfunction Devices Market by Product 2020?2026 (%)

Table 109 Global Erectile Dysfunction Devices Market by Geography 2020?2026 (\$ million)

Table 110 Global Erectile Dysfunction Devices Market by Geography 2020?2026 (%)



## I would like to order

Product name: Erectile Dysfunction Market - Global Outlook and Forecast 2021-2026

Product link: <https://marketpublishers.com/r/EAD56D14DBBEN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EAD56D14DBBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970